Director of Columbia University/New York Presbyterian Hospital Bronchiectasis Center
Angela DiMango, M.D.

Assistant Director
Claire Keating, M.D.

Associate Professor of Clinical Medicine
Columbia University College of Physicians and Surgeons

For appointments please call:

Make a Gift

What is Bronchiectasis?

Bronchiectasis is a lung disease characterized by enlarged small airways that collect mucus and cause recurrent lung infections. Symptoms include chronic cough, breathlessness, chest pain, fevers and weight loss. There are many different causes of bronchiectasis including inherited, infections, immune system abnormalities and rheumatologic diseases. Sometimes no cause is identified. Patients with bronchiectasis may also have Nontuberculous Mycobacteria (NTM) infections that may be difficult to treat.

New York-Presbyterian/Columbia University Medical Center offers a multidisciplinary Bronchiectasis program that optimizes the care of patients. These include experienced Pulmonologists, Respiratory Therapists, Infectious Disease consultants, Endocrinologists, Nutrionists and Thoracic Surgeons. Treatment is not the same for all patients and requires carefully individualized therapy.

We are currently one of 14 centers maintaining a Bronchiectasis Research Registry which collects information to better understand patients with Non Cystic Fibrosis Bronchiectasis and patients with Non Tuberculous Mycobacteria (NTM) infections. It allows easy identification of patients who may be eligible for our clinical trials. We have been conducting several clinical trials studying various treatments for bronchiectasis.

Current Clinical Trials

Bronchiectasis and NTM Research Registry/COPD Foundation
The Bronchiectasis Research Registry is a consolidated database of non-cystic fibrosis (non-CF) Bronchiectasis and Nontuberculosis Mycobacteria (NTM) patients from multiple clinical institutions. The goal of the Bronchiectasis Research Registry is to support collaborative research and assist in the planning of multi-center clinical trials for the treatment of NTM and non-CF Bronchiectasis, a progressive, non-curable disease of the lungs, which afflicts thousands of patients. The Registry will also be used to provide better insight into the study of the different types of Bronchiectasis, as well as the pathophysiology of the disorder. In 2012, in collaboration with NTM Info and Research, Inc (NTMir) and the consortium members, the COPD Foundation expanded the Bronchiectasis Research Registry to enroll patients with "non tuberculous mycobacteria (NTM) only."

INS-212 LAI Trial
A Randomized, Open-label, Multicenter Study of Liposomal Amikacin for Inhalation (LAI) in Adult Patients With Nontuberculous Mycobacterial (NTM) Lung Infection Caused by Mycobacterium Avium Complex (MAC) That Are Refractory to Treatment.

A Phase 2a, 2-part,Randomized, Double-blind, Placebo-controlled, Incomplete Block Crossover Study to Evaluate the Safety and Efficacy of VX-371 Solution for Inhalation With and Without Oral Ivacaftor in Subjects With Primary Ciliary Dyskinesia.


Keith Brenner, MD
Angela DiMango, MD
Emily DiMango, MD
Claire Keating, MD
Wilson Quezada, MD
Neil Schluger, MD
Byron Thomashaw, MD

How to Help

Individual and corporate support advances research that will help us to better understand and treat bronchiectasis, develop new therapies and create a centralized program to advance patient care. Please join this effort by making a tax-deductible donation.

Make Gift


To learn more about supporting bronchiectasis research, please contact:

Allison Quinn
Director of Development
Columbia University Irving Medical Center

We invite you to learn about the many ways a gift today can help improve the lives of individuals and their families now and for generations to come. Thank you for your interest and support.